Drug Trial Radar · NCT01135680
Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
May 2010
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Arm 1: Primary Objective: • To determine the safety and tolerability of multiple ascending, supratherapeutic doses of HPN-100. Arm 2: Primary Objective: • To assess the effects of steady-state levels of HPN-100 metabolites (4 phenylbutyric acid \[PBA\], phenylacetic acid \[PAA\], and phenylacetylglutamine \[PAGN\]) on 12-lead electrocardiogram (ECG) parameters in healthy male and female subjects with the primary endpoint being the time-matched change from baseline in the QT interval corrected for heart rate (HR) based on an individual correction method (QTcI).
Conditions
- Drug Toxicity
Interventions
HPN-100Drug
single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
HPN-100 or PlaceboDrug
single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
PlaceboDrug
single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
MoxifloxacinDrug
single oral 400-mg dose on study Day 3
HPN-100Drug
single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
HPN-100Drug
single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability as measured by the rate and severity of adverse events in each treatment group.Time frame: 3-day treatment period
- Changes from baseline QTcI as a measure of effects of study-state HPN-100 metabolites: PBA, PAA, and PAGNTime frame: 4 treatment regimens for 3 days with a 4 day minimum washout period between treatments
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Pharmacology, Inc.
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.